+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Oral Anti-Diabetes Drugs Market - Growth, Trends, and Forecast (2012 - 2024)

  • ID: 4758276
  • Report
  • 110 pages
  • Mordor Intelligence
UP TO OFF
until Jul 01st 2019
1 of 5

FEATURED COMPANIES

  • Astellas
  • AstraZeneca
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Eli Lilly
  • Janssen Pharmaceuticals
  • MORE
Market Overview

The global oral anti-diabetes drug market is estimated to be USD 39.2 billion in 2019, and it is growing because of the rise in the Type 2 diabetes population.

Approximately 10% of diabetes cases worldwide contribute to Type 1 diabetes, and 90% of diabetes cases contribute to Type 2 diabetes.

The number of people who have diabetes is likely to reach 592 million by 2035. In 2013, the economic costs of diabetes across the world were estimated to be USD 548 billion.

Thus, the rise in prevalence of diabetes worldwide is likely to create a vast demand for diabetes drugs.

Scope of the Report

The global oral anti-diabetes drug market is segmented by drugs (biguanides, alpha-glucosidase inhibitors, dopamine-D2 receptor agonists, SGLT-2 inhibitors, DPP-4 inhibitors, sulfonylureas, and meglitinides) and geography.

A holistic study of the market has been carried out by incorporating various factors, extending from country-specific demographic conditions and business cycles to market-specific macroeconomic influences that are needed to analyze future trends. The research uncovers many paradigm shifts in the market studied, in terms of brand-level market dynamics.

Key Market Trends - DPP-4 Inhibitors Segment Has the Largest Market Share

The DPP-4 inhibitors segment of the global oral anti-diabetes drug market was valued at USD 10,538.6 million in 2018, and it is expected to record a CAGR of 3.82% during the forecast period (2019-2024).
DPP-4 inhibitor drugs are gaining momentum in the market because the products do not seem to have any effect on primary adverse cardiovascular outcomes and risk for heart failure.

Besides, they can be used both as a combination therapy with insulin, sulphonylureas, and dipeptidyl peptidase-4 drugs, and as a monotherapy, thus, making it a widely used class of drugs.

During the forecast period, the DPP-4 inhibitors segment is expected to witness constant growth rate, due to the introduction of new drugs that have improved efficacy, like glucagon-like peptide (GLP-1) and sodium-glucose co-transporter-2 (SGLT-2) inhibitors. The segment is still expected to maintain the largest market share among all oral anti-diabetes drugs market segments.

Asia Pacific leading the Oral Anti-diabetes Drugs Market

Currently, North America holds the major share in the oral anti-diabetes drugs market. However, Asia-Pacific is expected to experience the highest growth rate during the forecast period.
This is due to the high prevalence of diabetes in this region, which caused consequent adverse health and economic consequences.
Moreover, an increase in the launch of new drugs with improved efficacy and high reimbursement for medicines is expected to have a positive impact on the oral anti-diabetes drugs market.
India, China, and Japan lead the market, due to the growing diabetes population in the Asia-Pacific region.

Competitive Landscape

The global oral anti-diabetes drugs market is consolidated, with few major manufacturers having a global market presence, while the remaining manufacturers are confined to the other local or region-specific manufacturers.

The innovations in diabetes drugs market like, Novo Nordisk Semaglutide (first oral GLP-1 agonist) performed better than expected against Januvia.
Oramed is performing research on the new molecule ORMD-0801, which is the first oral insulin capsule that has the most convenient and safest way to deliver insulin therapy. This drug is expected to be a game changer in the insulin and oral anti-diabetes drugs markets.

As part of this package, any purchases made up to 30th June will receive the following:

1) Free update of the report in 6 months on request 

2) Free Market Estimate sheet excel data sheet
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Astellas
  • AstraZeneca
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Eli Lilly
  • Janssen Pharmaceuticals
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Drug
5.1.1 Biguanides (Value and Volume 2012-2024)
5.1.1.1 Metformins
5.1.2 Alpha-glucosidase inhibitors (Value and Volume 2012-2024)
5.1.2.1 Alpha-glucosidase Inhibitors
5.1.3 Dopamine -D2 Receptor Agonist (Value and Volume 2012-2024)
5.1.3.1 Bromocriptin (Cycloset)
5.1.4 Sodium - glucose Cotransport -2 (SGLT-2) inhibitor (Value and Volume 2012-2024)
5.1.4.1 Invokana (Canagliflozin)
5.1.4.2 Jardiance (Empagliflozin)
5.1.4.3 Farxiga/Forxiga (Dapagliflozin)
5.1.4.4 Suglat (Ipragliflozin)
5.1.5 Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors (Value and Volume 2012-2024)
5.1.5.1 Januvia (Sitagliptin)
5.1.5.2 Onglyza (Saxagliptin)
5.1.5.3 Tradjenta (Linagliptin)
5.1.5.4 Vipidia/Nesina (Alogliptin)
5.1.5.5 Galvus (Vildagliptin)
5.1.6 Sulfonylureas (Value and Volume 2012-2024)
5.1.6.1 Sulfonylureas
5.1.7 Meglitinides (Value and Volume 2012-2024)
5.1.7.1 Meglitinides
5.2 Geography
5.2.1 North America
5.2.1.1 United States (Value and Volume 2012-2024)
5.2.1.1.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
5.2.1.2 Canada (Value and Volume 2012-2024)
5.2.1.2.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
5.2.1.3 Rest of North America (Value and Volume 2012-2024)
5.2.1.3.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
5.2.2 Europe
5.2.2.1 France (Value and Volume 2012-2024)
5.2.2.1.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
5.2.2.2 Germany (Value and Volume 2012-2024)
5.2.2.2.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
5.2.2.3 Italy (Value and Volume 2012-2024)
5.2.2.3.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
5.2.2.4 Spain (Value and Volume 2012-2024)
5.2.2.4.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
5.2.2.5 United Kingdom (Value and Volume 2012-2024)
5.2.2.5.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
5.2.2.6 Russia (Value and Volume 2012-2024)
5.2.2.6.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
5.2.2.7 Rest of Europe (Value and Volume 2012-2024)
5.2.2.7.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
5.2.3 Latin America
5.2.3.1 Mexico (Value and Volume 2012-2024)
5.2.3.1.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
5.2.3.2 Brazil (Value and Volume 2012-2024)
5.2.3.2.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
5.2.3.3 Rest of Latin America (Value and Volume 2012-2024)
5.2.3.3.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
5.2.4 Asia-Pacific
5.2.4.1 Japan (Value and Volume 2012-2024)
5.2.4.1.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
5.2.4.2 South Korea (Value and Volume 2012-2024)
5.2.4.2.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
5.2.4.3 China (Value and Volume 2012-2024)
5.2.4.3.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
5.2.4.4 India (Value and Volume 2012-2024)
5.2.4.4.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
5.2.4.5 Australia (Value and Volume 2012-2024)
5.2.4.5.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
5.2.4.6 Vietnam (Value and Volume 2012-2024)
5.2.4.6.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
5.2.4.7 Malaysia (Value and Volume 2012-2024)
5.2.4.7.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
5.2.4.8 Indonesia (Value and Volume 2012-2024)
5.2.4.8.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
5.2.4.9 Philippines (Value and Volume 2012-2024)
5.2.4.9.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
5.2.4.10 Thailand (Value and Volume 2012-2024)
5.2.4.10.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
5.2.4.11 Rest of Asia-Pacific (Value and Volume 2012-2024)
5.2.4.11.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
5.2.5 Middle East & Africa
5.2.5.1 Saudi Arabia (Value and Volume 2012-2024)
5.2.5.1.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
5.2.5.2 Iran (Value and Volume 2012-2024)
5.2.5.2.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
5.2.5.3 Egypt (Value and Volume 2012-2024)
5.2.5.3.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
5.2.5.4 Oman (Value and Volume 2012-2024)
5.2.5.4.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
5.2.5.5 South Africa (Value and Volume 2012-2024)
5.2.5.5.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
5.2.5.6 Rest of Middle & Africa (Value and Volume 2012-2024)
5.2.5.6.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

6 MARKET INDICATORS
6.1 Type 1 Diabetes Population (2012-2024)
6.2 Type 2 Diabetes Population (2012-2024)

7 COMPETITIVE LANDSCAPE
7.1 Company Profiles
7.1.1 Takeda
7.1.2 Pfizer
7.1.3 Eli Lilly
7.1.4 Janssen Pharmaceuticals
7.1.5 Astellas
7.1.6 Boehringer Ingelheim
7.1.7 Merck And Co.
7.1.8 AstraZeneca
7.1.9 Bristol Myers Squibb
7.1.10 Novartis
7.1.11 Sanofi

8 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Takeda
  • Pfizer
  • Eli Lilly
  • Janssen Pharmaceuticals
  • Astellas
  • Boehringer Ingelheim
  • Merck And Co.
  • AstraZeneca
  • Bristol Myers Squibb
  • Novartis
  • Sanofi
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4758276
Adroll
adroll